Furthermore, researchers have found that the KRAS mutation, commonly found in NSCLC tumors, increased the recruitment of Th17 cells, which was vital in generating and sustaining inflammation during the early stages of cancer (73). This evidence concerns the gene KRAS and non-small cell lung carcinoma.